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1991-7902/Copyrightª 2015, AssociatioSummary Background/purpose: Adrenocorticotropic hormone (ACTH) plays a vital role in
maintaining the function of the hypothalamicepituitaryeadrenal axis. Recent studies have
demonstrated that ACTH directly affects the proliferation and differentiation of bone cells.
However, the ACTH concentrations used in these studies appear to be markedly higher than
the physiological concentrations. Here, we investigated whether ACTH at pathophysiological
concentration affects the proliferation and differentiation of osteoblasts and osteoclasts.
Materials and methods: We evaluated the effect of ACTH at pathophysiological concentration
on osteoclasts using tartrate-resistant acid phosphatase staining and on osteoblasts using alka-
line phosphatase activity assay. Additionally, we conducted reverse transcriptase-polymerase
chain reaction analysis.
Results: We found that at pathophysiological concentration, ACTH does not affect osteoblast
proliferation and inhibits osteoblast differentiation. Moreover, we showed that at pathophys-
iological concentration, ACTH does not affect the proliferation of bone marrow macrophages,
but promotes differentiation of osteoclasts and induces expression of genes involved in bone
resorption.t of Oral and Maxillofacial Surgery, Saitama Medical University, 38 Moro-hongou, Moroyama-machi,
d.ac.jp (T. Sato).
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Effect of ACTH on bone cells 457Conclusion: Taken together, our findings suggest that ACTH modulates the proliferation and
differentiation of bone cells in vitro at pathophysiological concentration.
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Tooth extraction is a common treatment modality for
dental problems and is accompanied by damage to the bone
tissue. In addition, dentists are increasingly examining pa-
tients with depressive disorder, which is the fourth leading
cause of disability worldwide and is expected to be the
second leading cause by 2020.1 As a defense response
against stress factors that lead to diseases such as depres-
sive disorder, including conditions of mental stress, the
hypothalamoepituitaryeadrenal (HPA) axis is activated to
maintain homeostasis.2 Therefore, there is a need to
determine the influence of stress hormones on bone
metabolism and how such mental stress affects the healing
of bone tissue in patients with depressive disorder who
undergo tooth extraction.
Bone tissue is continuously regulated to maintain ho-
meostasis via endocrine systems, the nervous system, and
mechanical adaptation.3e5 Bone homeostasis refers to the
balance between bone tissue formation by osteoblasts and
its degradation by osteoclasts. The function of these cells is
regulated by several factors, including cytokines and hor-
mones. Accumulating evidence has demonstrated that key
players in bone homeostasis include pituitary hormones
such as growth hormone, follicle-stimulating hormone,
thyroid-stimulating hormone, prolactin, and oxytocin.6
Adrenocorticotropic hormone (ACTH), which stimulates
the secretion of glucocorticoid from the adrenal cortex, is
one such stress hormone regulating the HPA axis. Hyper-
secretion of ACTH has been observed in patients suffering
from major depressive disorder,7 suggesting that the ef-
fects of high concentrations of ACTH on bone are worthy of
investigation.
Recent studies demonstrated that ACTH affects the
proliferation and differentiation of bone cells. ACTH at
109M promotes proliferation of human primary osteo-
blasts.8 ACTH at 108M promotes collagen type 1 expression
in human osteosarcoma cell line9 and induces expression of
osteoblastic differentiation-associated genes in murine
primary stromal cells.10 ACTH at 108M has also been re-
ported to promote osteoclast differentiation in murine os-
teoclasts.10 According to a previous study, however, the
concentration of ACTH was 281 pg/mL (6.2  1011M) in
wild-type mice and 1394 pg/mL (3.1  1010M) in melano-
cortin 2 receptor (MC2R; an ACTH receptor)-knockout mice,
which are animal models for familial glucocorticoid defi-
ciency.11 The former concentration of ACTH is considered
the “physiological” concentration, while the latter is
considered the “pathophysiological” concentration. In
MC2R-knockout mice, the ACTH level increased because of
deficiency in the negative feedback provided by cortico-
sterone, suggesting that this level is considered themaximum level of ACTH possible. However, the ACTH con-
centration of 108M used in previous studies is 100-fold
higher than the level found in MC2R-knockout mice.
Furthermore, other studies showed that the ACTH level was
6.7 pg/mL (1.5  1012M) in mice exposed to a novel
environmental stress12 and 100 pg/mL (2.2  1011M) in
corticotropin-releasing factor transgenic mice.13
In this study, we investigated whether ACTH affects the
proliferation and differentiation of osteoblasts and osteo-
clasts at pathophysiological concentration.
Materials and methods
Reagents
Recombinant human ACTH was purchased from Abcam
(Cambridge, UK).
Animals
All mice (C57BL/6) were obtained from Tokyo Laboratory
Animals Science, fed normal laboratory chow, and reared in
an environmentally controlled clean room. Experiments
were conducted according to the institutional guidelines
for ethical animal experiments.
Cell culture
Mouse osteoclasts were generated using previously estab-
lished in vitro protocols.14 In short, bone marrow cells ob-
tained from the tibia of 8- to 10-week-old female mice
were cultured in a-minimal essential medium (Wako;
Tokyo, Japan) containing 10% fetal bovine serum (Sigma-
Aldrich, St Louis, MO, USA) for 16e20 hours, and non-
adherent cells were harvested and cultured at a concen-
tration of 1  105 cells/cm2 for 2 days with 10 ng/mL
macrophage colony-stimulating factor (M-CSF) (Peprotech,
Rocky Hill, NJ, USA). Adherent cells were used as bone
marrow macrophages (BMMs). To obtain osteoclasts, BMMs
were further cultured with 100 ng/mL receptor activator of
nuclear factor kappa-B ligand (RANKL) (Oriental Yeast,
Tokyo, Japan) and 10 ng/mL M-CSF. We used M-CSF and
RANKL at these concentrations throughout the study. Mu-
rine primary osteoblasts were isolated from the calvaria
collected from newborn mice as previously described.15
Neonatal mouse calvaria were dissected free of adherent
soft tissue, washed in phosphate-buffered saline, and
sequentially digested with 0.2% dispase and 0.1% collage-
nase. We used the murine preosteoblastic cell line MC3T3-
E1. Both primary osteoblasts and MC3T3-E1 cells were
maintained in a-minimal essential medium containing 10%
458 T. Sato et alfetal bovine serum. For the osteoblastic differentiation
assay, cells were cultured in a conditioned medium con-
taining 50 mg/mL ascorbic acid and 10 mM b-glycer-
ophosphate in a growth medium. The medium was replaced
with fresh medium every 2e3 days. All cultures were
maintained at 37C in humidified air containing 5% CO2.
Tartrate-resistant acid phosphatase staining
Recombinant ACTH was added at the same time as RANKL
during the procedure described above. BMMs cultured with
M-CSF and RANKL for 5 days were fixed with 10% formalin
for 5 minutes to stain for tartrate-resistant acid phospha-
tase (TRAP). Thereafter, they were refixed with ethano-
l:acetone (50:50 v/v) for 1 minute and incubated in acetate
buffer (pH 4.8) containing naphthol AS-MX phosphate
(Sigma-Aldrich), fast red violet LB salt (Sigma-Aldrich), and
50mM sodium tartrate at room temperature. TRAP-positive,
multinucleated cells with more than three nuclei were
counted as osteoclasts. Results are representative of more
than four individual experiments.
Measurement of alkaline phosphatase activity
Cells, at a density of 2  104 cells, were placed in 24-well
plates. After reaching confluence, cells were incubated in
a conditioned medium with ACTH at the indicated con-
centration for 7 days. Alkaline phosphatase (ALP) activity
was assayed (Wako) as previously described.15 The mea-
surements are expressed as the means of three indepen-
dent experiments, with each data point based on four
replicates.
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from cells using ISOGEN (Nippon
Gene, Tokyo, Japan) and was subjected to reverse
transcriptase-polymerase chain reaction (RT-PCR) using a
SuperScript One-Step RT-PCR kit (Thermo Scientific, Wil-
mington, DE, USA) as previously described.14 The gene-
specific primer pairs used were matrix metalloproteinase
9 (MMP-9) sense, 50-GGCCTGGAAGATGATGTTGT-30, and
MMP-9 antisense, 50-AATGGTGAGGTTTTGCGTTC-30; and b-
actin sense, 50-AGAAGGACTCCTATGTGGGTGA-30, and b-
actin antisense, 50-CATGATCTGGGTCATCTTTTCA-30. In this
study, b-actin was used as a loading control. All samples
were examined in triplicate assays.
Quantitative real-time RT-PCR
To validate changes in gene expression, quantitative real-
time RT-PCR analysis was performed using the Applied
Biosystems Prism 7900HT Sequence Detection System
(Thermo Scientific) according to the manufacturer’s in-
structions, as previously described.14 Total RNA was
extracted from cells using ISOGEN (Nippon Gene). We used
a TaqMan-based detection system. The reverse-
transcriptase reaction was performed using High Capacity
RNA-to-cDNA Master Mix (Thermo Scientific). We performed
PCR amplification with real-time detection using TaqMan
Gene Expression Master Mix (Thermo Scientific) and TaqManGene Expression Assays (Thermo Scientific) for Bglap
(osteocalcin gene) (Mm03413826_mH) and GAPDH
(Mm03302249_g1), which was used as an endogenous con-
trol. Values were normalized to GAPDH using the 2eDDCt
method. All samples were examined in triplicate assays.
Statistical analysis
Comparisons between two groups were analyzed using
Student t tests, and comparisons among three groups were
analyzed using one-way analysis of variance and Bonferro-
nieDunn methods (P < 0.05). All values are represented as
mean  the standard error of the mean. Results are
representative examples of more than three independent
sets of experiments.
Results
Pathophysiological concentration of ACTH did not
affect proliferation but inhibited osteoblast
differentiation
We assessed whether ACTH at 3  1010M induced prolif-
eration and ALP activity in osteoblasts. Surprisingly, this
concentration significantly inhibited ALP activity and did
not promote proliferation of osteoblasts (Figs. 1A and 1B).
We also found that expression of Bglap, an osteoblast dif-
ferentiation marker, was significantly downregulated at this
ACTH concentration (Fig. 1C).
ACTH at pathophysiological concentration did not
affect proliferation of BMMs but promoted
differentiation of osteoclasts
We examined whether ACTH at 3  1010M would also
induce osteoclastogenesis. As expected, TRAP-positive cell
formation was significantly increased by ACTH at
3  1010M (Fig. 2A). Next, we examined whether ACTH at
3  1010M induced expression of MMP-9, which encodes a
marker for bone resorption. After incubation with M-CSF
and RANKL for 5 days, RT-PCR analysis revealed that MMP-9
expression was more strongly induced by ACTH at
3  1010M than by the control (Fig. 2B). Finally, we
assessed whether ACTH at 3  1010M affected prolifera-
tion of BMMs, and found that ACTH did not affect cell
proliferation at this concentration (Fig. 2C).
Discussion
ACTH is an agonist for five melanocortin receptors (known
as MC1R through MC5R), all of which are present in bone
cells.8 Although ACTH is capable of binding to these re-
ceptors,16 only MC2R is identified as a functional receptor in
osteoblast differentiation.10 ACTH induces vascular endo-
thelial growth factor expression in osteoblasts via MC2R to
promote osteoblast differentiation. However, ACTH at both
1  109M and 1  1010M concentrations tends to inhibit
collagen 1 expression in human osteoblastic-like cell line.9
Our results concur with this observation, where ACTH at
3  1010M inhibited ALP activity and osteocalcin
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Figure 1 Inhibition of osteoblast differentiation by ACTH at
pathophysiological concentration. (A) Effect of ACTH
(3  1010M) on proliferation of murine primary osteoblasts
incubated for 3 days. (B) Effect of ACTH (3  1010M) on ALP
activity in murine primary osteoblasts incubated for 7 days. (C)
Quantitative RT-PCR analysis of Bglap expression in MC3T3-E1
cells incubated for 14 days. Data are expressed as mean  SEM.
The results shown are representative of four independent ex-
periments. # P < 0.05. ACTH Z adrenocorticotropic hormone;
ALP Z alkaline phosphatase; RT-PCR Z reverse transcriptase-
polymerase chain reaction; SEM Z standard error of the
means; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.
Effect of ACTH on bone cells 459expression in osteoblasts (Fig. 1). On the other hand, ACTH
at 1  108M promoted osteoclast differentiation.10 In our
study, ACTH at 3  1010M increased the formation of
TRAP-positive cells (Fig. 2).
We showed that, at pathophysiological concentration,
ACTH inhibits osteoblast differentiation and promotes
osteoclast differentiation, suggesting that ACTH negatively
regulates bone cell function in vitro. On the other hand,
Zaidi et al10 demonstrated that exogenous ACTH (at physi-
ological concentration) prevents glucocorticoid-induced
osteonecrosis in vivo, and a high concentration
(1  108M) of ACTH (higher than pathophysiological con-
centration) promotes osteoblast differentiation in vitro.
Their results may support the notion that ACTH positively
regulates bone metabolism in vivo. They considered that
ACTH administration promotes osteoblast differentiation at
local sites. This raises the question whether or not local
ACTH concentration reaches a level higher than physiolog-
ical concentration (1  108M) due to the administration of
ACTH at physiological concentration. We speculate that
systemic action of ACTH may exert anabolic effects on bone
metabolism via an as-yet-unknown mechanism, including
via other melanocortin receptors that ACTH is capable of
binding to.16
ACTH is encoded by the pro-opiomelanocortin (POMC )
gene, which encodes numerous peptide hormones,
including a-, b-, and g-melanocyte-stimulating hormone,
b-lipotropin, and b-endorphin. Some hormones directly
affect bone metabolism. For example, systemic adminis-
tration of a-melanocyte-stimulating hormone increases
the bone turnover rate and decreases bone volume.17 In a
previous study with POMC-knockout mice, cortical thick-
ness was significantly increased, while changes in trabec-
ular bone were not significant.18 Moreover, patients with
familial glucocorticoid deficiency, a rare autosomal-
recessive disease characterized by glucocorticoid defi-
ciency, exhibit tall stature and have advanced bone
maturation in the radius and phalanges, with a delay seen
in the carpal bones.19 This suggests that MC2R signaling is
associated with bone homeostasis. These studies indicate
that the POMC family of proteins and MC2R play critical
roles in bone metabolism.
Excess levels of glucocorticoid result in inhibition of
osteoblast differentiation and promotion of osteoclast dif-
ferentiation.20 High concentrations of glucocorticoid and
ACTH in serum have been observed in patients with dis-
eases such as Cushing syndrome and major depressive dis-
order.21,22 It is well known that Cushing syndrome leads to
the development of osteoporosis.21 A recent study has
shown a strong association between major depressive dis-
order and low bone mass in adults.23 Traumatic stress,
which activates the HPA axis, has also been shown to exert
a negative impact on mouse bone development in vivo.24
These studies strongly suggest that stress hormones nega-
tively affect the function of bone cells, and that the HPA
axis plays a pivotal role in the regulation of bone meta-
bolism. Our study may provide important knowledge about
the relationship between stress hormones and bone meta-
bolism. On the other hand, our study has a limitation
because the results are obtained from in vitro experiments.
From the viewpoint of dental medicine, it is noteworthy
to study the delay in healing of bone tissue after surgical
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Figure 2 Promotion of osteoclast differentiation by ACTH at pathophysiological concentration. (A) Effect of ACTH (3  1010M)
on differentiation of osteoclasts incubated for 5 days: TRAP staining (left panel) and the number of TRAP-positive multinucleated
cells formed (right panel). (B) Effect of ACTH (3  1010M) on MMP-9 expression in osteoclasts incubated for 5 days using RT-PCR
analysis. Here, b-actin was used as a loading control. (C) Effect of ACTH (3  1010M) on proliferation of BMMs incubated for 3 days.
Data are expressed as means  SEM. The results shown are representative of four independent experiments. # P < 0.05.
ACTH Z adrenocorticotropic hormone; MMP-9 Z matrix metalloproteinase 9; RT-PCR Z reverse transcriptase-polymerase chain
reaction; SEM Z standard error of the means; TRAP Z tartrate-resistant acid phosphatase.
460 T. Sato et aldental treatments, such as tooth extraction, in patients
with major depressive disorder. Further studies are needed
to clarify how ACTH regulates bone metabolism using
genetically engineered animals such as MC2R-knockout
mice.
ACTH at pathophysiological concentration does not
affect osteoblast proliferation but inhibits osteoblast dif-
ferentiation. Moreover, it does not affect proliferation of
BMMs, but promotes differentiation of osteoclasts and in-
duces upregulation of bone resorption-related gene.
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